NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pat…
Medical - Diagnostics & Research
US, Fort Myers [HQ]
NEO/Financials
Wall Street · Earnings · Institutional Sentiment
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about NeoGenomics, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
E | E | E | E | E | E | |||||||
2015 | 0.0200 | -0.004 | 87 | 99 | 1 | 0.54 | 2 | 1 | 2 | -10 | 35 | 51 |
2016 | -0.0419 | 0.136 | 99 | 245 | -2 | -4 | 3 | 29 | -5 | 4 | 45 | 105 |
2017 | -0.0743 | 0.119 | 244 | 257 | -5 | -3 | 29 | 20 | 6 | 0.41 | 99 | 107 |
2018 | -0.0108 | 0.181 | 258 | 271 | 0.85 | 1 | 24 | 21 | 3 | 6 | 113 | 79 |
2019 | 0.0288 | 0.277 | 276 | 406 | 2 | 6 | 31 | 31 | 10 | 10 | 114 | 147 |
2020 | 0.0797 | 0.072 | 408 | 443 | 8 | -15 | 38 | 21 | 13 | -34 | 175 | 263 |
2021 | 0.0384 | -0.268 | 444 | 484 | 4 | -77 | 33 | 25 | -13 | -189 | 191 | 250 |
2022 | -0.0696 | -0.684 | 484 | 501 | -8 | -167 | 43 | -126 | -118 | -195 | 283 | 355 |
2023 | -1.1600 | -0.174 | 509 | 588 | -144 | -78 | -83 | -139 | -153 | -214 | 310 | 390 |
2024 | -0.7000 | 0.069 | 591 | 661 | -87 | 8 | -6 | 11 | -96 | -66 | 313 | 342 |
2025 | - | 0.201 | - | 724 | - | 25 | - | 12 | - | -73 | - | 374 |
2026 | - | 0.370 | - | 793 | - | 1.F11X | - | 1.F111 | - | 1.F1111 | - | 1.F1111 |
2027 | - | 0.450 | - | 862 | - | 0.F12X | - | 0.F121 | - | 0.F1211 | - | 0.F1211 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Overall Consensus
Grading Consensus
Price Target Consensus
-36.303% $5.46 · MISS
Nov. 6, 2024Price Then
$14.93
Price Target
$20.50
Price Now
$15.04